News
Eli Lilly’s Retevmo Wins Full FDA Approval, Expanded to More Lung Cancer Patients
The FDA has granted full approval to Eli Lilly’s RET inhibitor Retevmo for RET fusion-positive non-small cell lung cancer, broadening the label to include first-line patients. The decision, based on Phase III data, marks a key milestone for Lilly’s oncology portfolio.